In January 2011 The first meeting of the ACO Execution Collaborative will need place. The AMGA ACO Initiative is certainly sponsored by Daiichi-Sankyo, Phytel, Inc., and sanofi-aventis.. AMGA announces participation of 19 health systems in ACO Development Collaborative The American Medical Group Association today announced 19 leading medical groups and organized systems of care which will be participating in its ACO Development Collaborative, scheduled to have its first meeting in conjunction with the AMGA National Summit on Accountable Treatment Organizations .The biggest reductions in risk of death for FOLOTYN were seen in patients with non-squamous cell carcinoma. The basic safety profile of FOLOTYN was in keeping with that noticed and reported in previous FOLOTYN solid tumor research. The most common Quality 3-4 adverse event observed in sufferers treated with FOLOTYN was mucositis . Additional Grade 3-4 adverse occasions occurring in more than 5 % of individuals were fatigue, dyspnea, neutropenia, anemia and thrombocytopenia in sufferers treated with FOLOTYN and rash, dyspnea, exhaustion and anemia in patients treated with erlotinib. ‘We are delighted that the results of this trial demonstrated scientific activity of FOLOTYN in a randomized study in comparison to erlotinib, an accepted active agent in non-little cell lung cancer,’ stated Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics.